Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus: Results of a Twenty-Four-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Phase IIb Study

Overview

Journal Arthritis Rheumatol

Publisher Wiley

Specialty Rheumatology

Date 2017 Oct 27

PMID 29073347

Citations 96

Authors

Joan T Merrill

Daniel J Wallace

Stephen Wax

Amy Kao

Patricia A Fraser

Peter Chang

David Isenberg

Affiliations

Soon will be listed here.

Abstract

Objective: To evaluate the efficacy and safety of atacicept, an antagonist of B lymphocyte stimulator/APRIL-mediated B cell activation, in patients with systemic lupus erythematosus (SLE).

Methods: ADDRESS II is a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-arm, phase IIb study evaluating the safety and efficacy of atacicept in patients with SLE (ClinicalTrials.gov identifier NCT01972568). Patients with active, autoantibody-positive SLE receiving standard therapy were randomized (1:1:1) to receive atacicept (75 mg or 150 mg) or placebo for 24 weeks. The primary end point was the SLE responder index 4 (SRI-4) at week 24.

Results: The intent-to-treat (ITT) population included 306 patients. There was a trend toward an improved SRI-4 response rate with atacicept 75 mg (57.8%; adjusted odds ratio [OR] 1.78, P = 0.045) and 150 mg (53.8%; adjusted OR 1.56, P = 0.121) at week 24 as compared with placebo (44.0%) (primary analysis; using the screening visit as baseline). In a prespecified sensitivity analysis using study day 1 as baseline, a significantly larger proportion of patients receiving atacicept 75 mg and 150 mg achieved an SRI-4 response at week 24 compared with placebo. In predefined subpopulations with high levels of disease activity (HDA) at baseline, serologically active disease, or both, statistically significant improvements in the SRI-4 and SRI-6 response rates were seen with atacicept versus placebo. A severe risk of disease flare was reduced with atacicept therapy in both the ITT and the HDA populations. The risks of serious adverse events and serious or severe infection were not increased with atacicept as compared with placebo.

Conclusion: Atacicept treatment showed evidence of efficacy in SLE, particularly in HDA and serologically active patients. Reductions in disease activity and severe flare were observed with atacicept treatment, with an acceptable safety profile.

Citing Articles

Defining immune reset: achieving sustained remission in autoimmune diseases.

Junt T, Calzascia T, Traggiai E, da Costa A, Gergely P, Schett G Nat Rev Immunol. 2025; .

PMID: 40044810 DOI: 10.1038/s41577-025-01141-w.

Targeted Cellular Treatment of Systemic Lupus Erythematosus.

Athanassiou P, Athanassiou L, Kostoglou-Athanassiou I, Shoenfeld Y Cells. 2025; 14(3).

PMID: 39937001 PMC: 11816398. DOI: 10.3390/cells14030210.

Opportunities and limitations of B cell depletion approaches in SLE.

Stockfelt M, Teng Y, Vital E Nat Rev Rheumatol. 2025; 21(2):111-126.

PMID: 39815102 DOI: 10.1038/s41584-024-01210-9.

The importance of developing reproducible primary endpoints for clinical trials in systemic lupus erythematosus.

Yang B, Chen Y, Jiang J, Chang C, Wu H, Gershwin M Clin Rheumatol. 2024; 44(1):183-192.

PMID: 39579266 DOI: 10.1007/s10067-024-07236-4.

A rationally designed CD19 monoclonal antibody-triptolide conjugate for the treatment of systemic lupus erythematosus.

Wang L, Yin H, Jiang J, Li Q, Gao C, Li W Acta Pharm Sin B. 2024; 14(10):4560-4576.

PMID: 39525579 PMC: 11544386. DOI: 10.1016/j.apsb.2024.06.024.

References

Hochberg M . Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997; 40(9):1725. DOI: 10.1002/art.1780400928. View

Koyama T, Tsukamoto H, Miyagi Y, Himeji D, Otsuka J, Miyagawa H . Raised serum APRIL levels in patients with systemic lupus erythematosus. Ann Rheum Dis. 2004; 64(7):1065-7. PMC: 1755547. DOI: 10.1136/ard.2004.022491. View

Lisnevskaia L, Murphy G, Isenberg D . Systemic lupus erythematosus. Lancet. 2014; 384(9957):1878-1888. DOI: 10.1016/S0140-6736(14)60128-8. View

Belnoue E, Pihlgren M, McGaha T, Tougne C, Rochat A, Bossen C . APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells. Blood. 2008; 111(5):2755-64. DOI: 10.1182/blood-2007-09-110858. View

Isenberg D, Petri M, Kalunian K, Tanaka Y, Urowitz M, Hoffman R . Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2015; 75(2):323-31. DOI: 10.1136/annrheumdis-2015-207653. View

Isenberg D, Rahman A, Allen E, Farewell V, Akil M, Bruce I . BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus. Rheumatology (Oxford). 2005; 44(7):902-6. DOI: 10.1093/rheumatology/keh624. View

Cervera R, Khamashta M, Font J, Sebastiani G, Gil A, Lavilla P . Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore). 2003; 82(5):299-308. DOI: 10.1097/01.md.0000091181.93122.55. View

Navarra S, Guzman R, Gallacher A, Hall S, Levy R, Jimenez R . Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011; 377(9767):721-31. DOI: 10.1016/S0140-6736(10)61354-2. View

Hegazy M, Darwish H, Darweesh H, El-Shehaby A, Emad Y . Raised serum level of APRIL in patients with systemic lupus erythematosus: correlations with disease activity indices. Clin Immunol. 2010; 135(1):118-24. DOI: 10.1016/j.clim.2009.12.012. View

10.

Bertsias G, Ioannidis J, Boletis J, Bombardieri S, Cervera R, Dostal C . EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis. 2007; 67(2):195-205. DOI: 10.1136/ard.2007.070367. View

11.

DallEra M, Chakravarty E, Wallace D, Genovese M, Weisman M, Kavanaugh A . Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum. 2007; 56(12):4142-50. DOI: 10.1002/art.23047. View

12.

Lateef A, Petri M . Unmet medical needs in systemic lupus erythematosus. Arthritis Res Ther. 2013; 14 Suppl 4:S4. PMC: 3535719. DOI: 10.1186/ar3919. View

13.

Yu G, Boone T, Delaney J, Hawkins N, Kelley M, Ramakrishnan M . APRIL and TALL-I and receptors BCMA and TACI: system for regulating humoral immunity. Nat Immunol. 2001; 1(3):252-6. DOI: 10.1038/79802. View

14.

Benson M, Dillon S, Castigli E, Geha R, Xu S, Lam K . Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL. J Immunol. 2008; 180(6):3655-9. DOI: 10.4049/jimmunol.180.6.3655. View

15.

Rekvig O, van der Vlag J . The pathogenesis and diagnosis of systemic lupus erythematosus: still not resolved. Semin Immunopathol. 2014; 36(3):301-11. DOI: 10.1007/s00281-014-0428-6. View

16.

Furie R, Leon G, Thomas M, Petri M, Chu A, Hislop C . A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study. Ann Rheum Dis. 2014; 74(9):1667-75. DOI: 10.1136/annrheumdis-2013-205144. View

17.

Ota M, Duong B, Torkamani A, Doyle C, Gavin A, Ota T . Regulation of the B cell receptor repertoire and self-reactivity by BAFF. J Immunol. 2010; 185(7):4128-36. PMC: 3263398. DOI: 10.4049/jimmunol.1002176. View

18.

Zhang J, Roschke V, Baker K, Wang Z, Alarcon G, Fessler B . Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol. 2000; 166(1):6-10. DOI: 10.4049/jimmunol.166.1.6. View

19.

van Vollenhoven R, Kinnman N, Vincent E, Wax S, Bathon J . Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase II, randomized, placebo-controlled trial. Arthritis Rheum. 2011; 63(7):1782-92. DOI: 10.1002/art.30372. View

20.

McCarthy E, Lee R, Gabhann J, Smith S, Cunnane G, Doran M . Elevated B lymphocyte stimulator levels are associated with increased damage in an Irish systemic lupus erythematosus cohort. Rheumatology (Oxford). 2013; 52(7):1279-84. DOI: 10.1093/rheumatology/ket120. View